{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:27:50Z","timestamp":1774466870219,"version":"3.50.1"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114521","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T20:09:27Z","timestamp":1743106167000},"page":"114521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Non-antiviral therapies for viral infections: Harnessing host mechanisms"],"prefix":"10.1016","volume":"153","author":[{"given":"Sruthi","family":"Sarvepalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhadeepthi","family":"Vadarevu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114521_bb0005","first-page":"257","article-title":"Principles of virus structure. Encyclopedia of","author":"Sevvana","year":"2021","journal-title":"Virology"},{"issue":"291","key":"10.1016\/j.intimp.2025.114521_bb0010","article-title":"Is it time for microbiome-based therapies in viral infections?","volume":"2","author":"Sadiq","year":"2021","journal-title":"Virus Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0015","article-title":"Emerging pandemic diseases: how we got to COVID-19","volume":"182","author":"Dm","year":"2020","journal-title":"Cell [Internet]"},{"key":"10.1016\/j.intimp.2025.114521_bb0020","unstructured":"Baron S, Fons M, Albrecht T. Viral pathogenesis. In: Baron S, editor. Medical Microbiology [Internet]. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996 [cited 2025 Feb 27]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK8149\/."},{"key":"10.1016\/j.intimp.2025.114521_bb0025","unstructured":"Healthline [Internet]. 2018 [cited 2025 Feb 27]. Viral Diseases: List of Types & Contagiousness, Treatment, Prevention. Available from: https:\/\/www.healthline.com\/health\/viral-diseases."},{"key":"10.1016\/j.intimp.2025.114521_bb0030","first-page":"185","article-title":"Epidemiology of viral infections. Fenner and White\u2019s medical","author":"Burrell","year":"2017","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0035","first-page":"445","article-title":"Nine-year study of WHO virus reports on fatal viral infections","volume":"55","author":"Assaad","year":"1977","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.intimp.2025.114521_bb0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijid.2020.05.001","article-title":"Comparison of mortality associated with respiratory viral infections between December 2019 and march 2020 with that of the previous year in southeastern France","volume":"96","author":"Giraud-Gatineau","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2025.114521_bb0045","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.immuni.2020.05.004","article-title":"Respiratory virus infections: understanding COVID-19","volume":"52","author":"Subbarao","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.114521_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: A review","volume":"215","author":"Yuki","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.114521_bb0055","unstructured":"Antiviral Drug - an overview | ScienceDirect Topics [Internet]. [cited 2025 Feb 27]. Available from: https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/antiviral-drug."},{"issue":"35","key":"10.1016\/j.intimp.2025.114521_bb0060","article-title":"A review: mechanism of action of antiviral drugs","author":"Kausar","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"7925","key":"10.1016\/j.intimp.2025.114521_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/d41586-022-02282-x","article-title":"Designer antiviral takes aim at one of influenza's soft spots","volume":"609","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.114521_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101031","article-title":"Nanotechnology for virus treatment","volume":"36","author":"Zhou","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.intimp.2025.114521_bb0075","first-page":"1","article-title":"Influenza and antiviral resistance: an overview","volume":"13","author":"Lampejo","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0080","article-title":"Host directed therapies: COVID-19 and beyond","author":"Tripathi","year":"2021","journal-title":"Current Research in Pharmacology and Drug Discovery"},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cmi.2018.11.015","article-title":"Future management of viral diseases: role of new technologies and new approaches in microbial interactions","volume":"25","author":"Maggi","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0090","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10224","key":"10.1016\/j.intimp.2025.114521_bb0100","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S0140-6736(20)30305-6","article-title":"Reducing mortality from 2019-nCoV: host-directed therapies should be an option","volume":"395","author":"Zumla","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.114521_bb0105","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.19694.1","article-title":"Targeting viral entry as a strategy for broad-spectrum antivirals","volume":"8","author":"Mazzon","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.intimp.2025.114521_bb0110","doi-asserted-by":"crossref","unstructured":"Thom RE, D'Elia RV. Future applications of host direct therapies for infectious disease treatment. Front Immunol [Internet] 2024 Oct 1 [cited 2024 Oct 13];15. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2024.1436557\/full.","DOI":"10.3389\/fimmu.2024.1436557"},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0115","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1038\/s41467-023-42550-6","article-title":"Direct-acting antiviral resistance of hepatitis C virus is promoted by epistasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2025.114521_bb0120","doi-asserted-by":"crossref","first-page":"e00168","DOI":"10.1128\/CMR.00168-19","article-title":"Host-directed antiviral therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2025.114521_bb0125","article-title":"Host-targeting therapies for hepatitis C virus infection: current developments and future applications","author":"Crouchet","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/jmv.25683","article-title":"(George), Gao S. Global health concerns stirred by emerging viral infections","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114521_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/v10090453","article-title":"Host-directed antivirals: A realistic alternative to fight Zika virus","volume":"10","author":"Saiz","year":"2018","journal-title":"Viruses"},{"issue":"43","key":"10.1016\/j.intimp.2025.114521_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2020.07.009","article-title":"Recent advances in antiviral drug development towards dengue virus","author":"Troost","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.intimp.2025.114521_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104994","article-title":"Targeting host DEAD-box RNA helicase DDX3X for treating viral infections","volume":"185","author":"Winnard","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2025.114521_bb0150","doi-asserted-by":"crossref","unstructured":"A B, Ci T, F P, C P, C V, E D. DEAD-box helicase DDX3X as a host target against emerging viruses: new insights for medicinal chemical approaches. Journal of medicinal chemistry [Internet] 2022 Aug 11 [cited 2024 Oct 13];65(15). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35899912\/.","DOI":"10.1021\/acs.jmedchem.2c00755"},{"issue":"8","key":"10.1016\/j.intimp.2025.114521_bb0155","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: from discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.114521_bb0160","unstructured":"Hart R. Forbes. More Infectious And Airborne Covid-19 Mutant Replaced Wuhan Virus To Dominate Worldwide, Research Finds. Available from: https:\/\/www.forbes.com\/sites\/roberthart\/2020\/11\/13\/more-infectious-and-airborne-covid-19-mutant-replaced-wuhan-virus-to-dominate-worldwide-research-finds\/."},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0165","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.intimp.2025.114521_bb0180","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.clinthera.2019.07.017","article-title":"\u201cHere today, gone tomorrow\u201d or \u201cHere today, stay a long while\u201d: the divergent paths of two host factors important in viral infections","volume":"41","author":"Jhaveri","year":"2019","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114521_bb0190","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3389\/fimmu.2020.01209","article-title":"Host directed therapy against infection by boosting innate immunity","author":"Bergman","year":"2020","journal-title":"Front. Immunol."},{"issue":"77","key":"10.1016\/j.intimp.2025.114521_bb0195","article-title":"Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection","author":"Konwar","year":"2021","journal-title":"Tetrahedron"},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/pathogens13020164","article-title":"The role of the nuclear factor-kappa B (NF-\u03baB) pathway in SARS-CoV-2 infection","volume":"13","author":"Kesika","year":"2024","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0205","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-020-01415-w","article-title":"Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents","volume":"17","author":"Khadke","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2025.114521_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110080","article-title":"Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll","volume":"143","author":"Shahzad","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"16","key":"10.1016\/j.intimp.2025.114521_bb0215","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.7150\/thno.48076","article-title":"SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy","volume":"10","author":"Datta","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2025.114521_bb0220","first-page":"1","article-title":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors\u2014lessons from available evidence and insights into COVID-19","author":"Kai","year":"2020","journal-title":"Hypertens. Res."},{"issue":"24","key":"10.1016\/j.intimp.2025.114521_bb0225","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s13054-020-03166-0","article-title":"Blocking IL-1 to prevent respiratory failure in COVID-19","author":"van de Veerdonk","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.intimp.2025.114521_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102442","article-title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy","volume":"109","author":"Ceribelli","year":"2020","journal-title":"J. Autoimmun."},{"issue":"538","key":"10.1016\/j.intimp.2025.114521_bb0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbrc.2020.10.080","article-title":"The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy","author":"Santopolo","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2025.114521_bb0240","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3389\/fimmu.2020.01022","article-title":"Highlight of immune pathogenic response and Hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection","author":"Liang","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114521_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102569","article-title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review","volume":"19","author":"Alijotas-Reig","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2025.114521_bb0250","doi-asserted-by":"crossref","unstructured":"Singh M, Wit E de. Antiviral agents for the treatment of COVID-19: Progress and challenges. CR Med [Internet]. 2022 Mar 15 [cited 2024 Oct 13];3(3). Available from: https:\/\/www.cell.com\/cell-reports-medicine\/abstract\/S2666-3791(22)00055-6.","DOI":"10.1016\/j.xcrm.2022.100549"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2025.114521_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/ijmr.IJMR_585_20","article-title":"Perspectives for repurposing drugs for the coronavirus disease 2019","volume":"151","author":"Cherian","year":"2020","journal-title":"Indian J. Med. Res."},{"issue":"148","key":"10.1016\/j.intimp.2025.114521_bb0260","article-title":"The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?","author":"Mahooti","year":"2020","journal-title":"Microb. Pathog."},{"issue":"6","key":"10.1016\/j.intimp.2025.114521_bb0265","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcyt.2020.11.001","article-title":"Stem cell therapy in coronavirus disease 2019: current evidence and future potential","volume":"23","author":"Shetty","year":"2021","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.intimp.2025.114521_bb0270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.medmal.2019.10.004","article-title":"Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)","volume":"50","author":"Bleibtreu","year":"2020","journal-title":"Med. Mal. Infect."},{"issue":"3","key":"10.1016\/j.intimp.2025.114521_bb0275","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/JVI.02935-13","article-title":"Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus","volume":"88","author":"Raj","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2025.114521_bb0280","doi-asserted-by":"crossref","unstructured":"Roy AN, Gupta AM, Banerjee D, Chakrabarti J, Raghavendra PB. Unraveling DPP4 receptor interactions with SARS-CoV-2 variants and MERS-CoV: insights into pulmonary disorders via Immunoinformatics and molecular dynamics. Viruses 2023 15(10):2056.","DOI":"10.3390\/v15102056"},{"key":"10.1016\/j.intimp.2025.114521_bb0285","unstructured":"Boktor SW, Hafner JW, Doerr C. Influenza (Nursing). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Oct 15]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568788\/."},{"issue":"3","key":"10.1016\/j.intimp.2025.114521_bb0290","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.4081\/hr.2019.8268","article-title":"Influenza virus B-associated hemophagocytic lymphohistiocytosis","volume":"11","author":"Gao","year":"2019","journal-title":"Hematol. Rep."},{"issue":"135","key":"10.1016\/j.intimp.2025.114521_bb0295","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejmech.2017.04.070","article-title":"Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus","author":"Tonelli","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197246","article-title":"Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells","volume":"13","author":"Estrin","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2025.114521_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109826","article-title":"Etoposide-based therapy for severe forms of COVID-19","volume":"142","author":"Hamizi","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0310","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP2977","article-title":"Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral","volume":"21","author":"Silveira","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.intimp.2025.114521_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.197885","article-title":"Host microRNAs and exosomes that modulate influenza virus infection","volume":"279","author":"Zheng","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.intimp.2025.114521_bb0320","author":"CDC. Influenza (Flu)."},{"issue":"11","key":"10.1016\/j.intimp.2025.114521_bb0325","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/pathogens9110898","volume":"9","author":"Masmejan","year":"2020","journal-title":"Zika Virus. Pathogens"},{"key":"10.1016\/j.intimp.2025.114521_bb0330","doi-asserted-by":"crossref","unstructured":"Dahiya N, Yadav M, Singh H, Jakhar R, Sehrawat N. ZIKV: epidemiology, infection mechanism and current therapeutics. Front Trop Dis [Internet] 2023 Jan 23 [cited 2024 Oct 13];3. Available from: https:\/\/www.frontiersin.org\/journals\/tropical-diseases\/articles\/10.3389\/fitd.2022.1059283\/full.","DOI":"10.3389\/fitd.2022.1059283"},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0335","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/applmicrobiol2040059","article-title":"Zika virus infection and development of drug therapeutics","volume":"2","author":"Guo","year":"2022","journal-title":"Appl. Microbiol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114521_bb0340","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/v10090453","article-title":"Host-directed antivirals: A realistic alternative to fight Zika virus","volume":"10","author":"Saiz","year":"2018","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0345","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.celrep.2018.12.095","article-title":"Zika virus dependence on host Hsp70 provides a protective strategy against infection and disease","volume":"26","author":"Taguwa","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2025.114521_bb0350","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3389\/fimmu.2020.01209","article-title":"Host directed therapy against infection by boosting innate immunity","volume":"11","author":"Bergman","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114521_bb0355","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/v10090453","article-title":"Host-directed antivirals: A realistic alternative to fight Zika virus","volume":"10","author":"Saiz","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2025.114521_bb0360","unstructured":"Dengue | CDC Yellow Book 2024 [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/infections-diseases\/dengue."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2025.114521_bb0365","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiw423","article-title":"Current status of dengue therapeutics Research and Development","volume":"215","author":"Low","year":"2017","journal-title":"J Infect Dis"},{"issue":"138","key":"10.1016\/j.intimp.2025.114521_bb0370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.antiviral.2016.11.019","article-title":"Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo","author":"Warfield","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2025.114521_bb0375","first-page":"1","article-title":"Targeting human inosine 5\u2032 monophosphate dehydrogenase type 2 for anti-dengue lead identification - a computational approach","volume":"22","author":"Lr","year":"2024","journal-title":"Journal of biomolecular structure & dynamics"},{"issue":"27","key":"10.1016\/j.intimp.2025.114521_bb0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12929-019-0614-x","article-title":"Role of microRNAs in antiviral responses to dengue infection","author":"Wong","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2025.114521_bb0385","unstructured":"Ojeda Rodriguez JA, Haftel A, Walker III. Chikungunya Fever. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Oct 15]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534224\/."},{"issue":"12","key":"10.1016\/j.intimp.2025.114521_bb0390","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01788-20","article-title":"Small-molecule inhibitors of chikungunya virus: mechanisms of action and antiviral drug resistance","volume":"64","author":"Kovacikova","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.intimp.2025.114521_bb0395","doi-asserted-by":"crossref","first-page":"1139808","DOI":"10.3389\/fimmu.2023.1139808","article-title":"TLR4 is one of the receptors for chikungunya virus envelope protein E2 and regulates virus induced pro-inflammatory responses in host macrophages","author":"Mahish","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114521_bb0400","doi-asserted-by":"crossref","unstructured":"Freppel W, Silva LA, Stapleford KA, Herrero LJ. Pathogenicity and virulence of chikungunya virus. Virulence. 15(1):2396484.","DOI":"10.1080\/21505594.2024.2396484"},{"issue":"4","key":"10.1016\/j.intimp.2025.114521_bb0405","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/microorganisms8040589","article-title":"Ferritin: an inflammatory player keeping Iron at the Core of pathogen-host interactions","volume":"8","author":"Moreira","year":"2020","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.intimp.2025.114521_bb0410","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fcimb.2020.00410","article-title":"Engineering CAR T cells to target the HIV reservoir","author":"Mu","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"38","key":"10.1016\/j.intimp.2025.114521_bb0415","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coviro.2019.06.004","article-title":"HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy","author":"Balcom","year":"2019","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0420","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3390\/ijms25052621","article-title":"HIV reservoirs and treatment strategies toward curing HIV infection","volume":"25","author":"Matsuda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114521_bb0425","doi-asserted-by":"crossref","unstructured":"Jp D, Cb C, B H. Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders. Frontiers in oncology [Internet]. 2019 Mar 15 [cited 2024 Oct 15];9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30931253\/.","DOI":"10.3389\/fonc.2019.00127"},{"key":"10.1016\/j.intimp.2025.114521_bb0430","doi-asserted-by":"crossref","unstructured":"Hoover K, Higginbotham K. Epstein-Barr Virus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Oct 15]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559285\/.","DOI":"10.58662\/9783965434578-15"},{"issue":"82","key":"10.1016\/j.intimp.2025.114521_bb0435","doi-asserted-by":"crossref","first-page":"ftae002","DOI":"10.1093\/femspd\/ftae002","article-title":"Awakening the sleeping giant: Epstein\u2013Barr virus reactivation by biological agents","author":"Indari","year":"2024","journal-title":"Pathog Dis."},{"issue":"9","key":"10.1016\/j.intimp.2025.114521_bb0440","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/cancers12092565","article-title":"Targeted therapies for Epstein-Barr virus-associated lymphomas","volume":"12","author":"Pei","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.114521_bb0445","unstructured":"About Cytomegalovirus (CMV) and Congenital CMV - MN Dept. of Health [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/www.health.state.mn.us\/diseases\/cytomegalovirus\/aboutcmv.html."},{"key":"10.1016\/j.intimp.2025.114521_bb0450","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fimmu.2017.00566","article-title":"Hepatitis C virus and human cytomegalovirus-natural killer cell subsets in persistent viral infections","volume":"8","author":"Pollmann","year":"2017","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2025.114521_bb0455","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02227-16","article-title":"Extracellular interactions between hepatitis C virus and secreted apolipoprotein E","volume":"91","author":"Li","year":"2017","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114521_bb0460","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4254\/wjh.v7.i3.498","article-title":"MiR-122 in hepatitis B virus and hepatitis C virus dual infection","volume":"7","author":"Song","year":"2015","journal-title":"World J. Hepatol."},{"issue":"33","key":"10.1016\/j.intimp.2025.114521_bb0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mib.2016.05.017","article-title":"Antisense antimicrobial therapeutics","author":"Sully","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"issue":"20","key":"10.1016\/j.intimp.2025.114521_bb0470","article-title":"A concise review on impacts of microRNAs in biology and medicine of hepatitis C virus","author":"Moradi","year":"2020","journal-title":"Gene Reports."},{"issue":"19","key":"10.1016\/j.intimp.2025.114521_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115679","article-title":"SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection","volume":"28","author":"Li","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0480","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","volume":"99","author":"Lin","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2025.114521_bb0485","doi-asserted-by":"crossref","unstructured":"Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J. Infect. 2014 68(1):1\u201320.","DOI":"10.1016\/j.jinf.2013.08.019"},{"issue":"6","key":"10.1016\/j.intimp.2025.114521_bb0490","doi-asserted-by":"crossref","first-page":"908","DOI":"10.5604\/01.3001.0012.7191","article-title":"Immunometabolic effect of cholesterol in hepatitis C infection: implications in clinical management and antiviral therapy","volume":"17","author":"Gonz\u00e1lez-Aldaco","year":"2018","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.intimp.2025.114521_bb0495","unstructured":"CDC. Ebola. 2024 [Cited 2024 Oct 15]. Ebola Disease Basics. Available from: https:\/\/www.cdc.gov\/ebola\/about\/index.html."},{"key":"10.1016\/j.intimp.2025.114521_bb0500","doi-asserted-by":"crossref","unstructured":"Jain S, Khaiboullina SF, Baranwal M. Immunological perspective for Ebola virus infection and various treatment measures taken to fight the disease. Pathogens 2020 9(10):850.","DOI":"10.3390\/pathogens9100850"},{"issue":"40","key":"10.1016\/j.intimp.2025.114521_bb0505","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2015.09.005","article-title":"Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections","author":"Zumla","year":"2015","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.114521_bb0510","article-title":"The ability of Zika virus intravenous immunoglobulin to protect from or enhance Zika virus disease","author":"Pinto","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114521_bb0515","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4269\/ajtmh.20-1578","article-title":"Results of a double-blind, randomized, placebo-controlled phase 1 study to evaluate the safety and pharmacokinetics of anti-Zika virus immunoglobulin","volume":"105","author":"White","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.intimp.2025.114521_bb0520","article-title":"An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: the COVIFERON II randomized controlled trial","volume":"99","author":"Darazam","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.114521_bb0525","author":"HKU Scholars Hub: Project [Internet]. [cited"},{"key":"10.1016\/j.intimp.2025.114521_bb0530","doi-asserted-by":"crossref","unstructured":"Viox EG, Bosinger SE, Douek DC, Schreiber G, Paiardini M. Harnessing the power of IFN for therapeutic approaches to COVID-19. J. Virol. 2024 98(5):e01204\u201323.","DOI":"10.1128\/jvi.01204-23"},{"key":"10.1016\/j.intimp.2025.114521_bb0535","unstructured":"Baylor Research Institute. An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C [Internet]. clinicaltrials.gov; 2016 Nov [cited 2024 Oct 15]. Report No.: NCT00163657. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00163657."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0540","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14787210.2022.2020097","article-title":"Therapeutic potential of 5-aminolevulinic acid and sodium-ferrous citrate for viral insults: relevance to the COVID-19 crisis","volume":"20","author":"Negoro","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.intimp.2025.114521_bb0545","doi-asserted-by":"crossref","unstructured":"Kaketani K, Nakajima M. Case Reports: Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate, an Inducer of Heme Oxygenase 1, in Combination with Sodium Ferrous Citrate for the Treatment of COVID-19 Patients. [cited 2025 Feb 27]; Available from: https:\/\/opencovidjournal.com\/VOLUME\/1\/PAGE\/52\/.","DOI":"10.2174\/2666958702101010052"},{"key":"10.1016\/j.intimp.2025.114521_bb0550","doi-asserted-by":"crossref","unstructured":"Darwish A, Almadani A, Alsalman J, Atkin S, Murad M, Nakajima M, et al. Safety and immune-supportive potential of the food supplement 5-aminolevulinic acid phosphate for patients with COVID-19: An open-label, non-randomized pilot study. Bioactive Compounds in Health and Disease - Online ISSN: 2574\u20130334; Print ISSN: 2769\u20132426. 2024 Jan 19;7(1):17\u201335.","DOI":"10.31989\/bchd.v7i1.1290"},{"issue":"12","key":"10.1016\/j.intimp.2025.114521_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111477","article-title":"Therapeutic potential of 5-aminolevulinic acid in metabolic disorders: Current insights and future directions","volume":"27","author":"Kuryata","year":"2024","journal-title":"iScience"},{"issue":"16","key":"10.1016\/j.intimp.2025.114521_bb0560","first-page":"4492","article-title":"Development of gelatin methacrylate (GelMa) hydrogels for versatile intracavitary applications. Biomaterials","volume":"10","author":"S. Kulkarni N, Chauhan G, Goyal M, Sarvepalli S, Gupta V.","year":"2022","journal-title":"Science"},{"issue":"91","key":"10.1016\/j.intimp.2025.114521_bb0565","article-title":"Development of rapidly soluble mebendazole nanosuspension for colorectal cancer","author":"Patel","year":"2024","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.intimp.2025.114521_bb0570","doi-asserted-by":"crossref","unstructured":"Sarvepalli S, Parvathaneni V, Chauhan G, Shukla SK, Gupta V. Inhaled indomethacin-loaded liposomes as potential therapeutics against non-small cell lung Cancer (NSCLC). Pharm. Res. 2022 39(11):2801\u201315.","DOI":"10.1007\/s11095-022-03392-x"},{"key":"10.1016\/j.intimp.2025.114521_bb0575","unstructured":"Mann SK, Marwaha R. Chlorpromazine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Oct 15]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553079\/."},{"issue":"12","key":"10.1016\/j.intimp.2025.114521_bb0580","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/molecules27123651","article-title":"Chlorpromazine, a clinically approved drug, inhibits SARS-CoV-2 Nucleocapsid-mediated induction of IL-6 in human monocytes","volume":"27","author":"Karwaciak","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.intimp.2025.114521_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106274","article-title":"Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine","volume":"57","author":"Plaze","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2025.114521_bb0590","unstructured":"Rezk A. Administration of Chlorpromazine as a Treatment for COVID-19 [Internet]. clinicaltrials.gov; 2020 Jul [cited 2024 Oct 15]. Report No.: NCT04354805. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04354805."},{"key":"10.1016\/j.intimp.2025.114521_bb0595","unstructured":"Centre Hospitalier St Anne. Repurposing of Chlorpromazine in Covid-19 Treatment [Internet]. clinicaltrials.gov; 2024 Jul [cited 2024 Oct 15]. Report No.: NCT04366739. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04366739."},{"key":"10.1016\/j.intimp.2025.114521_bb0600","unstructured":"Study Details | The Effect of Chloroquine in the Treatment of Patients With Dengue | ClinicalTrials.gov [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00849602."},{"key":"10.1016\/j.intimp.2025.114521_bb0605","unstructured":"Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? - PMC [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7564151\/."},{"key":"10.1016\/j.intimp.2025.114521_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108268","article-title":"Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?","volume":"165","author":"Singh","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0615","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03725-2020","article-title":"Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial","volume":"58","author":"Rocco","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0620","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03725-2020","article-title":"Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial","volume":"58","author":"Rocco","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"184","key":"10.1016\/j.intimp.2025.114521_bb0625","article-title":"Iminosugars: A host-targeted approach to combat Flaviviridae infections","author":"Evans DeWald","year":"2020","journal-title":"Antiviral Res."},{"issue":"129","key":"10.1016\/j.intimp.2025.114521_bb0630","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","article-title":"Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4","author":"Warfield","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2025.114521_bb0635","unstructured":"Emergent BioSolutions. Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects [Internet]. clinicaltrials.gov; 2024 Mar [cited 2024 Oct 15]. Report No.: NCT02696291. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02696291."},{"key":"10.1016\/j.intimp.2025.114521_bb0640","unstructured":"Emergent BioSolutions. Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects [Internet]. clinicaltrials.gov; 2024 Mar [cited 2024 Oct 15]. Report No.: NCT02061358. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02061358."},{"key":"10.1016\/j.intimp.2025.114521_bb0645","unstructured":"LI L. The effect of CAR-T cell therapy on the reconstitution of HIV-specific immune function [internet]. clinicaltrials.gov; 2022 Sep [cited 2024 Oct 15]. Report No.: NCT03240328. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03240328."},{"key":"10.1016\/j.intimp.2025.114521_bb0650","unstructured":"Cairo M. A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients [Internet]. clinicaltrials.gov; 2024 May [cited 2024 Oct 15]. Report No.: NCT03266640. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03266640."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0655","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2019","journal-title":"Cell Prolif."},{"key":"10.1016\/j.intimp.2025.114521_bb0660","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijid.2020.05.040","article-title":"Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of mesenchymal stromal (stem) cell (MSC) therapy \u2014 achieving global consensus and visibility for cellular host-directed therapies","volume":"96","author":"Zumla","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0665","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","author":"Meng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.114521_bb0670","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcyt.2020.07.002","article-title":"Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment","volume":"24","author":"Raza","year":"2022","journal-title":"Cytotherapy"},{"issue":"111","key":"10.1016\/j.intimp.2025.114521_bb0675","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","article-title":"Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients","author":"van der Ree","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2025.114521_bb0680","unstructured":"Santaris Pharma A/S. A Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection [Internet]. clinicaltrials.gov; 2014 Jan [cited 2024 Oct 15]. Report No.: NCT01727934. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01727934."},{"key":"10.1016\/j.intimp.2025.114521_bb0685","unstructured":"Hoffmann-La Roche. Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection [Internet]. clinicaltrials.gov; 2018 Feb [cited 2024 Oct 15]. Report No.: NCT02452814. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02452814."},{"key":"10.1016\/j.intimp.2025.114521_bb0690","unstructured":"Santaris Pharma A/S. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (Miravirsen) Administered to Treatment-Na\u00efve Subjects With Chronic Hepatitis C (CHC) Infection [Internet]. clinicaltrials.gov; 2012 Jan [cited 2024 Oct 15]. Report No.: NCT01200420. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01200420."},{"issue":"1","key":"10.1016\/j.intimp.2025.114521_bb0695","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/cells9010220","article-title":"miRNAs as Influencers of Cell\u2013Cell Communication in Tumor Microenvironment","volume":"9","author":"Conti","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0700","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jiph.2018.08.005","article-title":"A review on current trends in the treatment of human infection with H7N9-avian influenza A","volume":"12","author":"Sivanandy","year":"2019","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.intimp.2025.114521_bb0705","unstructured":"Study Details | Single Dose Escalating Study of DAS181 in Adults | ClinicalTrials.gov [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00527865?a=21."},{"key":"10.1016\/j.intimp.2025.114521_bb0710","doi-asserted-by":"crossref","unstructured":"Griensven J van, Edwards T, Lamballerie X de, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 2016 374(1):33\u201342.","DOI":"10.1056\/NEJMoa1511812"},{"key":"10.1016\/j.intimp.2025.114521_bb0715","unstructured":"Clinical Research Management, Inc. A Phase I\/II Pilot Clinical Trial to Evaluate the Efficacy and Safety of Ebola Virus Disease (EVD) Convalescent Plasma (ECP) for Treatment of EVD [Internet]. clinicaltrials.gov; 2015 Jan [cited 2020 Dec 23]. Report No.: NCT02333578. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02333578."},{"key":"10.1016\/j.intimp.2025.114521_bb0720","unstructured":"Home | ClinicalTrials.gov [Internet]. [cited 2024 Oct 15]. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.intimp.2025.114521_bb0725","unstructured":"Zika virus [Internet]. [cited 2025 Mar 1]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/zika-virus."},{"key":"10.1016\/j.intimp.2025.114521_bb0730","unstructured":"CDC. COVID-19. 2024 [cited 2025 Mar 1]. Types of COVID-19 Treatment. Available from: https:\/\/www.cdc.gov\/covid\/treatment\/index.html."},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0735","article-title":"Efficacy and limitations of repurposed drugs and vaccines for COVID-19","author":"Murmu","year":"2024","journal-title":"Journal of Medicine, Surgery, and Public Health"},{"issue":"9","key":"10.1016\/j.intimp.2025.114521_bb0740","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/v16091367","article-title":"Central and peripheral nervous system manifestations associated with dengue illness","volume":"16","author":"Guzman","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2025.114521_bb0745","unstructured":"Dengue and severe dengue [Internet]. [cited 2025 Mar 1]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"10.1016\/j.intimp.2025.114521_bb0750","unstructured":"CDC. Chikungunya Virus. 2024 [cited 2025 Mar 1]. Symptoms, Diagnosis, & Treatment. Available from: https:\/\/www.cdc.gov\/chikungunya\/symptoms-diagnosis-treatment\/index.html."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.idnow.2024.104938","article-title":"A meta-analysis of chikungunya virus in neurological disorders","volume":"54","author":"da Costa","year":"2024","journal-title":"Infectious Diseases Now."},{"issue":"9","key":"10.1016\/j.intimp.2025.114521_bb0760","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/138161206776055813","article-title":"Limitations of current antiretroviral agents and opportunities for development","volume":"12","author":"Jain","year":"2006","journal-title":"CPD"},{"key":"10.1016\/j.intimp.2025.114521_bb0765","unstructured":"CDC. Epstein-Barr Virus and Infectious Mononucleosis. 2024 [cited 2025 Mar 1]. About Epstein-Barr Virus (EBV). Available from: https:\/\/www.cdc.gov\/epstein-barr\/about\/index.html."},{"issue":"5","key":"10.1016\/j.intimp.2025.114521_bb0770","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with Valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.intimp.2025.114521_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcvp.2023.100150","article-title":"Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir\/velpatasvir plus ribavirin for 24 weeks","volume":"3","author":"Fedorchenko","year":"2023","journal-title":"Journal of Clinical Virology Plus"},{"key":"10.1016\/j.intimp.2025.114521_bb0780","unstructured":"CDC. Influenza (Flu). 2024 [cited 2025 Mar 1]. Influenza Antiviral Drug Resistance. Available from: https:\/\/www.cdc.gov\/flu\/treatment\/antiviralresistance.html."},{"key":"10.1016\/j.intimp.2025.114521_bb0785","unstructured":"CDC. Middle East Respiratory Syndrome (MERS). 2024 [cited 2025 Mar 1]. About Middle East Respiratory Syndrome (MERS). Available from: https:\/\/www.cdc.gov\/mers\/about\/index.html."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925005119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:07:36Z","timestamp":1744506456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925005119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":157,"alternative-id":["S1567576925005119"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114521","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-antiviral therapies for viral infections: Harnessing host mechanisms","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114521"}}